Proactive - Interviews for investors
Medicus Pharma files Orphan Drug application for SkinJect in rare skin Cancer indication
Medicus Pharma has submitted an Orphan Drug Designation application to the U.S. FDA for its SkinJect therapy, targeting basal cell carcinoma in patients with the rare genetic disorder Gorlin Syndrome. This non-surgical microneedle treatment aims to address a significant unmet…